Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

NCT02228421 · clinicaltrials.gov ↗

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Sponsor

PeriPharm

Collaborators

[object Object]
[object Object]